Regulatory innovation and drug development for early-stage Alzheimer's disease

New England Journal of Medicine

Volumn 368, Issue 13, 2013, Pages 1169-1171

  Kozauer, Nicholas ^a   Katz, Russell ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ADL DISABILITY; ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; COGNITIVE DEFECT; DRUG APPROVAL; DRUG CONTROL; DRUG RESEARCH; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL DISEASE; HUMAN; NEUROIMAGING; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; TREATMENT OUTCOME;

EID: 84875514732     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1302513     Document Type: Article

References (5)

1. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
2. Guidance for industry: Alzheimer's disease: developing drugs for the treatment of early stage disease. Washington, DC: Center for Drug Evaluation and Research, February 2013 (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf).
3. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
4. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27.
5. Albert MS, Blacker D, Moss MB, Tanzi R, McArdle JJ. Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology 2007;21:158-69. (Pubitemid 46631098)